Claim Missing Document
Check
Articles

Found 26 Documents
Search

The Correlation Between Type and Stage of Lung Cancer with The Chronic Obstructive Pulmonary Disease Group at Arifin Achmad Hospital, Pekanbaru Gurning, Andi Sarikawan; Munir, Sri Melati; Yunus, Faisal; Fauzi, Zarfiardy Aksa; Adrianison, Adrianison; Yovi, Indra; Indriani, Sri Indah
Jurnal Respirologi Indonesia Vol 45 No 2 (2025)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v45i2.512

Abstract

Background: The relationship between lung cancer (LC) and chronic obstructive pulmonary disease (COPD) has been extensively studied but is still up for debate. COPD is a molecularly based illness and one of the independent risk factors for lung cancer, particularly squamous cell carcinoma. This study uses spirometry to assess the relationship between the type and stage of LC and COPD in a group of LC patients at Arifin Achmad Hospital. Methods: This cross-sectional study was conducted on lung cancer patients in Arifin Achmad Hospital, Pekanbaru, from June 2022 to December 2022. Based on spirometry examination, patients were grouped according to the degree of COPD. Then, the relationship between the COPD group and the type and degree of cancer was determined. Results: The study involved 52 patients predominantly male (71.2%), aged over 40 years (92.3%), Smokers and former smokers with Severe Brinkman index (69.2%), restrictive lung function (34.6%), COPD group D (40.4%), adenocarcinoma (61.5%), stage IV lung cancer (92,3%) and WHO Performance Status Scale 2 (61.5%). The FEV1/FVC rate in this study was 66.67%. There is a link between the stage of lung cancer and the group of COPD (P=0.001). Conclusion: There is a relation between the stage of LC in the COPD group, which is predominantly with stage IV lung cancer, and group D of COPD.
Indonesian Society of Respirology Position Paper on Lung Cancer Control in Indonesia Andarini, Sita; Santoso, Andintia Aisyah; Arfiansyah, Mochammad Aris; Syahruddin, Elisna; Zaini, Jamal; Putra, Andika Chandra; Kurniawan, Ferry Dwi; Ermayanti, Sabrina; Soeroso, Noni Novisari; Munir, Sri Melati; Infianto, Andreas; Setijadi, Ana Rima; Setyawan, Ungky Agus; Wulandari, Laksmi; Haryati, Haryati; Jasminarti, Ida Ayu; Hidayat, Moulid; Santoso, Arif
Jurnal Respirologi Indonesia Vol 44 No 4 (2024)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v44i4.884

Abstract

Lung cancer is a major health concern in Indonesia due to its increasing prevalence, late-stage diagnosis, younger population, and high mortality. Addressing this issue requires nationwide implementation of comprehensive lung cancer control, which includes risk reduction and prevention strategies, focusing on tobacco control and air pollution mitigation. Screening with low-dose computed tomography (LDCT) and early detection in symptomatic patients, along with TB screening programs and all non-communicable diseases, is strongly recommended to enhance early case findings, treatment effectiveness, and overall patient outcomes. A multidisciplinary team (MDT) approach is important to ensure accurate diagnosis and comprehensive care. Moreover, the integration of palliative care at the early stages of advanced lung cancer is vital, focusing on symptom management and enhancing the quality of life for patients. While national guidelines are available for the diagnosis and treatment of lung cancer, significant disparities in healthcare access remain across Indonesia. Thus, it is essential to improve universal health coverage and referral systems to guarantee equal access to lung cancer care for patients at all levels through advocacy and ease of access.
Bagaimana Bekas Tuberkulosis Dapat Menginduksi Kanker Paru? Simatupang, Elvando Tunggul Mauliate; Simanjuntak, Arya Marganda; Yovi, Indra; Simbolon, Rohani Lasmaria; Munir, Sri Melati; Wijaya, Dewi
Majalah Kedokteran Indonesia Vol 73 No 6 (2023): Journal of The Indonesian Medical Association - Majalah Kedokteran Indonesia, Vo
Publisher : PENGURUS BESAR IKATAN DOKTER INDONESIA (PB IDI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.47830/jinma-vol.73.6-2024-1087

Abstract

In 2022, there will be 10.6 million cases of tuberculosis, which is a serious problem worldwide. Thailand's cohort research after the COVID-19 pandemic found a 7-fold risk of tuberculosis infection in COVID-19 patients, pointing to a probable rise in TB cases. In order to completely eradicate TB, care must be given to patients both before and after infection, guaranteeing public health against TB infection.1,2
Aspergillosis in Lung Cancer: A Narrative Literature Review Yarsy, Pofi Risanti; Sri Melati Munir
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 8 No. 3 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v8i3.935

Abstract

Aspergillosis is one of the complications of lung cancer and lung cancer treatment. Diagnosis of Aspergillosis in lung cancer, in general, is still a challenge because clinical symptoms and examination results are not typical, and risk factors often go unnoticed. To simplify the diagnosis of Aspergillosis, several criteria have been created based on the patient's condition, clinical and radiological features, and mycological laboratory examination. Doctors' vigilance still needs to be increased, examination facilities are still limited in certain cities, and diagnostic services have not been integrated, so management is not optimal. This literature review aims to increase doctors' knowledge and awareness regarding aspergillosis in lung cancer, which is an important step to improve the appropriate management of this disease.
Ki-67 Expression and Histopathological Type, Metastatic Status, and Risk Factors in Lung Cancer Khairani, Muhammad; Munir, Sri Melati; Darmawi, Darmawi; Yovi, Indra; Esha, Indi; Fauzi, Zarfiardy Aksa; Zahtamal, Zahtamal
Jurnal Respirasi Vol. 12 No. 1 (2026): January 2026
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v12-I.1.2026.35-43

Abstract

Introduction: Lung cancer remains a leading cause of cancer-related morbidity and mortality worldwide. In Indonesia, the incidence and death rates associated with this disease remain alarmingly high. Ki-67 is a potential biomarker for assessing cellular proliferation and metastatic potential. However, its clinical application in lung cancer remains inconsistent. This study aimed to analyze the association between Ki-67 expression and histopathological subtype, metastatic status, and clinical risk factors in patients with lung cancer. Methods: This study enrolled 42 patients diagnosed with lung cancer at Arifin Achmad General Hospital, Pekanbaru, Indonesia. Statistical analysis used the Chi-square or Fisher’s exact test (non-parametric tests) for categorical data and the Kolmogorov-Smirnov test, depending on the data characteristics. Participants were selected based on predefined inclusion criteria, complete medical documentation, and available Ki-67 immunohistochemistry results. Results: Among the 42 patients analyzed, 34 (80.9%) exhibited metastasis. The findings revealed a significant correlation between Ki-67 expression and metastasis (p=0.0038), whereas no significant associations were observed with age, sex, smoking status, or histopathological classification. Most patients (approximately 69%) had low Ki-67 expression. Conclusion: Ki-67 expression was associated with metastatic status in patients with lung cancer and might serve as a prognostic biomarker. Further studies with larger sample sizes are needed to validate these findings.
The effect of systemic chemotherapy on hematological profiles in lung cancer patients Amarudin, Amarudin; Munir, Sri Melati
Media Penelitian dan Pengembangan Kesehatan Vol. 36 No. 1 (2026): MEDIA PENELITIAN DAN PENGEMBANGAN KESEHATAN
Publisher : Poltekkes Kemenkes Bandung

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.34011/jmp2k.v36i1.3610

Abstract

Background: Cancer is a disease characterized by uncontrolled cell growth in one or both lungs originating from epithelial cells. In Indonesia, lung cancer ranks fourth among all cancer types and is the second leading cause of death after cardiovascular diseases. Management of lung cancer involves various therapeutic modalities, including surgery, radiotherapy, chemotherapy, and combination therapy. Certain chemotherapeutic agents, such as cisplatin and carboplatin, are known to have a narrow therapeutic index and high toxicity, so inappropriate regimen selection or dosing may result in serious adverse effects or even death. All chemotherapy agents carry the potential for toxicity, including both hematological and non-hematological effects, with hematological toxicities commonly manifesting as anemia, leukopenia, and thrombocytopenia of varying severity. Objective: This study aimed to determine the hematologic profile in patients after chemotherapy. Methods: This study was a descriptive research with a cross-sectional design using a total sampling technique. During the August-December 2023 period, 36 lung cancer patients met the inclusion criteria at Arifin Achmad Hospital, namely lung cancer patients with adenocarcinoma or squamous cell carcinoma who underwent advanced chemotherapy with a cycle of 21 days in the August-December 2023 period. Results: Of the 36 patients, 29 (80.56%) were male. The highest age of patients undergoing chemotherapy was ≥ 40 years (94.44%). Changes in the hematological profile after chemotherapy occurred in 14 patients (38.89%), with the most common hematological profile being anemia. Conclusion: The use of chemotherapy regimens can cause changes in the hematologic profile, including anemia, leukopenia, and thrombocytopenia.